πŸ‡ΊπŸ‡Έ FDA
Patent

US 10221161

Inhibitors of plasma kallikrein

granted A61PA61P1/00A61P1/18

Quick answer

US patent 10221161 (Inhibitors of plasma kallikrein) held by KalVista Pharmaceuticals Limited expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61P, A61P1/00, A61P1/18, A61P11/00, A61P13/12